I don't see anything that makes me disagree. Watching the conferences complete with compelling slides showing horrific wounds being healed and cartilage growing in properly where none existed before have demonstrated to me this company is now different from many other stem cell companies. Their products are no longer promise, they are real, and they work, very very well, both in wound care with a 70% closure on persistent wounds and on the cartilage replacement scaffold which ingrows with the right type of cartilage. I've seen other cartilage products that result in cartilage but not as strong as the original, this looks like the real deal. Put 35% quarter over quarter revenue growth in and that's enough for me. I predict these products and others will slowly permeate into the market and into the public's consciousness until there is a bubble in stem cell companies, again!, and those who get in early in the right companies will profit enormously. Of course, all stocks are subject to manipulation, so either play along or ignore.